Nachrichten zur Karolinska Development AB Aktie

Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets

STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out…

Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation

STOCKHOLM, SWEDEN – May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Development portfolio company OssDsign will change CEO during second half of 2025

STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a…

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

STOCKHOLM, SWEDEN – January 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has…

Karolinska Developments portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO

STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has…

Interim Report - January-September 2024

STOCKHOLM – 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2024. The…

Karolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment

STOCKHOLM, SWEDEN, November 5 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has…

Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024

STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has…

Interim Report - January-June 2024

STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The…

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

STOCKHOLM, SWEDEN – July 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition…

Karolinska Development invests in BOOST Pharma, expanding its portfolio

STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has invested in…

Karolinska Development’s Annual General Meeting 2024

STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting…

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Interim Report - January-March 2024

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The…

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Development Annual Report 2023 published

STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2023.…

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a…

Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD

STOCKHOLM, SWEDEN – March 6, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

dpa-AFX ProFeed